4 key Advantages
There are 3 main competitors for RHISE that are producing stroke diagnostic instruments. We compared RHISE to these 3 competitors using 4 key criteria:
1. Ability to differentiate stroke types
2. Accuracy greater than 95%
3. Low sale price
4. Portability of the device
Currently, CT scans are the only device in the market that differentiates between the two different types of stroke. The other two closest competitors are Valtari Bio [1] and Sarissa Biomedical U.K. [2] and they are in their clinical trial stages. Since these two companies are unable to differentiate between stroke types, our main competitor is the CT scan manufacturers. In comparison to CT, RHISE has a similar accuracy, a much lower price, and is more portable. A key advantage of RHISE compared to CT is its ability to be used in an ambulance and outside the hospital setting. CT machines can only be used in hospital facilities and thus limits the diagnosis and treatment of stroke to the hospital.
RHISE presents the opportunity to move both diagnosis and treatment of stroke outside of the hospital, drastically reducing the time a patient goes before receiving treatment, and reducing the risk of both permanent disability and death in stroke patients.
•••
References
- Valtari Bio. 2014 Jan 03 [accessed 2016 Dec 9]. https://www.valtaribio.com.htm
- Sarissa Biomedical. 2002 Nov [accessed 2016 Dec 9]. https://www.sarissa-biomedical.com.htm